Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Muxiang Shunqi Pill is a traditional Chinese medicine (TCM) formulation developed and marketed by Shandong Wohua Pharmaceutical Polytron Technologies. It is primarily indicated for the treatment of qi stagnation, abdominal distension, and digestive disorders. The formulation typically comprises a blend of herbal ingredients, including *Aucklandia lappa* (Muxiang), *Amomum villosum*, *Cyperus rotundus*, betel nut, licorice, tangerine peel, *Magnolia officinalis*, *Citrus aurantium*, *Atractylodes*, and green bark. Its therapeutic mechanism involves promoting qi circulation, dispersing dampness, and strengthening the spleen and stomach to alleviate gastrointestinal discomfort. It is administered orally in pill form and is an approved product in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on muxiang shunqi pill.